Today there are more recipients waiting for organ transplants than there are organs available. And while the current opioid crisis has produced more available organs for transplantation, those with hepatitis C viral infection have previously been considered ineligible. With a new antiviral treatment regimen, could it be possible to transplant these organs, prevent the establishment of hepatitis C in the recipients, and produce an excellent outcome in patients? A team of infectious disease experts, transplant physicians and surgeons from the Brigham proved, with an effectiveness of 100 percent, that it is.